Trial Profile
Phase II Study of Safety and Efficacy of Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Sep 2020 Status changed from active, no longer recruiting to completed.
- 30 May 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 05 Mar 2012 New trial record